Liver Cancer Meeting – Link to Slideshows

Liver Cancer rates and deaths are rising all over the world; much of this increase is due to hepatitis C. Three of us from HepCBC attended a Liver Cancer (hepatocellular carcinoma or HCC) conference on Feb. 11th in Toronto, sponsored by the Canadian Assn. for the Study of the Liver (CASL). There will be an article summarizing the most interesting findings in the hepc.bull newsletter soon. Meanwhile, here is a link to the Powerpoint slides:http://www.hepato

Updates to Canadian sofosbuvir pricing and CADTH queuing schedule

NEW CANADIAN DEVELOPMENTS RE: SOFOSBUVIR'S PRICE AND APPROVAL SCHEDULE GILEAD PRICING OF SOFOSBUVIROn Feb. 24th, 2014 Gilead Sciences announced $55,000 Canadian pricing for its sofosbuvir (SOVALDI™) treatment which is significantly lower than the $84,000 that is being quoted for the USA, and actively opposed by patient advocacy groups there:  "Gilead Sciences Canada Inc. is committed to ensuring the best possible market access for HCV patients who would be

Fighting to make HCV treatment affordable for 170 million people

Bangkok, Thailand, Feb. 28, 2014 (press release): "Thirty-eight activists from 22 countries joined forces at the first-ever Hepatitis C Virus (HCV) World Community Advisory Board (CAB) to demand equitable access to treatment for hepatitis C virus (HCV) from six multinational pharmaceutical companies. Yet AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, and Roche refused to provide a plan for equitable access to treatment for HCV, a curable infection t